Printer Friendly

Distribution of bovine spongiform encephalopathy in greater kudu (Tragelaphus strepsiceros).

Of all the species exposed naturally to the bovine spongiform encephalopathy (BSE) agent, the greater kudu (Tragelaphus strepsiceros), a nondomesticated bovine from Africa, appears to be the most susceptible to the disease. We present the results of mouse bioassay studies to show that, contrary to findings in cattle with BSE in which the tissue distribution of infectivity is the most limited recorded for any of the transmissible spongiform encephalopathies (TSE), infectivity in greater kudu with BSE is distributed in as wide a range of tissues as occurs in any TSE. BSE agent was also detected in skin, conjunctiva, and salivary gland, tissues in which infectivity has not previously been reported in any naturally occurring TSE. The distribution of infectivity in greater kudu with BSE suggests possible routes for transmission of the disease and highlights the need for further research into the distribution of TSE infectious agents in other host species.

**********

To date, 13 species of zoo animal have been confirmed as having died with a novel scrapie-like spongiform encephalopathy (SE) concurrent with the bovine spongiform encephalopathy (BSE) epidemic (Table 1). The disease is thought, in some, if not all, of these species, to be caused by infection with the BSE agent. In addition, natural infection with BSE has been reported in five species of primate in French zoos (11), but these results are considered equivocal for the confirmation of a spongiform encephalopathy (12, G.A.H. Wells, unpub. data). BSE was diagnosed in six of eight greater kudu (Tragelaphus strepsiceros), a member of the family Bovidae, subfamily Bovinae, that died at the London Zoo from 1989 through 1992 (2,13,14). The epidemiology of this disease in greater kudu is consistent with either a particularly high susceptibility to infection, the occurrence of direct animal-to-animal transmission of the disease, or with a combination of these factors (2,14,15). To investigate further the biology of BSE in greater kudu, the distribution of the infectious agent in greater kudu with BSE was determined by using the mouse bioassay method.

Materials and Methods

Tissues

Tissues from four greater kudu that died with spongiform encephalopathy were tested for infectivity by bioassay in C57B1-J6 mice (Table 2). The epidemiologic, clinical, and pathologic findings of the disease in the kudu have been described in detail previously (2,14 16), and a summary of the relevant details is given in Table 3. Tissues for bioassay were collected principally from kudu A 1212; each sample was collected in a sterile container by using new disposable instruments and gloves to prevent cross contamination between tissues. As TSE infectivity has been demonstrated previously by bioassay in tissues preserved in formalin and paraffin wax (13,17,18), tissue samples obtained opportunistically after routine postmortem examinations of three additional kudu (A664, A666, and A1221) were also tested for infectivity by using mouse bioassay. Samples collected from kudu A666, A1212, and A1221 were stored in separate, sterile containers and were either frozen at -20[degrees]C or fixed in neutral buffered 10% formalin. Non-neural tissues from kudu A664 were fixed in neutral buffered 10% formalin in a common container. The brain from this animal was the last organ removed at necropsy and was fixed in 10% formol saline in a separate container.

Previously, infectivity had been detected in formalin-fixed brain tissue from kudu A664 by bioassay using five inbred mouse strains, with similar incubation periods and lesion profiles to those demonstrated for the BSE agent from domestic cattle with BSE (13). Bioassay of brain from kudu A664 was not repeated in the current study, but a positive control sample of fresh brain tissue from clinically affected kudu A 1212 was tested.

Bioassay

The tissues injected into mice for BSE-bioassay are listed in Table 2. Most of the tissue homogenates were prepared from thawed samples of fresh tissues frozen at -20[degrees]C. Tissue homogenates prepared from formalin-fixed tissues were rinsed overnight in running water to leach out the fixative, while formalin-fixed, paraffin-embedded tissues were dewaxed in chloroform (two changes) and washed in several changes of absolute alcohol before being rehydrated by immersion in a series of aqueous solutions of descending concentrations of alcohol, through to 100% water. Material for each tissue homogenate was dissected from the center of each tissue sample by using single-use disposable instruments and rigorous sterile procedures. Each sample was homogenized in 10% physiologic saline to make a 10% wt/vol suspension, which was then passed through a gauze filter. To tissue homogenates containing distal ileum or feces, ampicillin was added at the rate of 1.25 mg/mL.

For each tissue homogenate, 20 C57B1-J6 mice (4-7 weeks old) were each injected by the intracranial route (0.02 mL) and by the intraperitoneal route (0.10 ml.). Single tissue or pooled tissue samples were prepared and injected into C57B1-J6 mice for a standard qualitative assay of infectivity (13,19).

Mice injected with different tissue or tissue-pool homogenates were housed in separate cages. Injected mice were coded, and detailed clinical monitoring of the mice was carried out by using a standard protocol. The clinical endpoint was determined when mice either showed clear signs of neurologic disease (20) or other deterioration of health. Surviving mice were killed 950 days after injection. Postmortem confirmation of disease in mice was routinely carried out by histopathologic examination of the brain for morphologic changes of spongiform encephalopathy.

After the histopathologic assessment of mice, immunohistochemical examination (IHC) for evidence of spongiform encephalopathy disease-specific PrP (Pr[P.sup.Sc]) was performed on the brains of all mice in selected tissue groups. The groups were mice in which either a low number were positive, testing was inconclusive on histopathologic assessment, or the results indicated a novel or anomalous distribution of the agent in kudu compared to that in other TSE. Additional groups of interest (skeletal muscle, endometrium, and mammary gland), which were negative on the histopathologic examination of mouse brains, were also examined by IHC. Immunohistochemical detection of Pr[P.sub.Sc] was introduced to the standard protocol to improve specificity and sensitivity of detecting BSE transmission to mice (21,22) and interpret inconclusive histopathologic results (23). For control purposes, the brains from mice that had been injected with pathologically affected cranial thoracic spinal cord from kudu A1212 were also immunostained. Brains from normal mice that were not injected with infected tissues were similarly examined to provide negative controls.

The immunohistochemical method used was essentially that applied previously to cattle central nervous system tissues (24) and adapted for use in mouse brain tissue. Anti-bovine Pr[P.sub.Sc] serum (971) was used at 1/8,000 and 1/16,000 dilutions in an avidin-biotin-peroxidase (ABC) complex technique. Transmission was defined by histopathologic evidence of spongiform encephalopathy, or, where applied, immunohistochemical presence of disease-specific PrP (Pr[P.sub.Sc]) in the brains of the mice.

Results

The results of the bioassay of tissues are given in Table 2. Based on the histopathologic examination of mouse brains, 15 of the 32 tissue homogenates were positive. The nine histopathologically positive groups examined immunohistochemically were confirmed positive by this method with marginal improved sensitivity of detection (2-3 more mice positive) in only three groups. For nine of the positive tissue homogenates, prepared from fresh central nervous, lymphoreticular, or distal ileum tissue, the proportion of positive mice ([greater than or equal to] 40%) indicated moderate or high levels of spongiform encephalopathy infectivity. The remaining six positive groups (Table 2) had low proportions of positive mice (6%-27%), indicative of relatively low titres or only traces of infectivity. Low numbers (12) of histopathologically inconclusive mice in five tissue homogenate groups, which included two groups (A1212, popliteal and submandibular lymph nodes) that contained no histopathologically positive mice, were resolved almost exclusively as negative when examined using immunohistochemistry. The one exception was an inconclusive mouse in A1212 retropharyngeal lymph node group, which proved immunohistochemically positive.

Discussion

Fifteen of the 32 kudu tissue homogenates transmitted BSE to mice. The positive result for brain tissue from kudu A1221 confirms the diagnosis of subclinical spongiform encephalopathy in this animal (15) and is the first to demonstrate transmission from a subclinical natural case of spongiform encephalopathy in a bovine species. Also, this report is the first of infectivity in the ileum from a field case of spongiform encephalopathy other than scrapie in sheep.

Apparently low titers or only traces of infectivity were detected in spleen, lung, submandibular salivary gland, conjunctiva, and skin. In bioassays of TSE infectivity, the possibility that trace levels of infectivity in tissues may represent postmortem or laboratory contamination of uninfected tissues with infected material has to be considered. Such an explanation is unlikely in the present study for the following reasons. Many of the tissues which contained only traces of infectivity were taken from kudu A1212, an animal from which tissues were collected by using rigorous sterile procedures to prevent cross-contamination, and no pattern between the order of tissue sampling and the bioassay results from this animal suggests a sequence of tissue contamination. A low incidence of disease in the mice or failure to detect infectivity from tissues previously fixed or processed to paraffin wax may be attributable to a reduced titer of infectivity, which can occur as a result of such treatments. The wide range of survival periods for positive mice in these assays (Table 2) is similar to those seen when brain tissue from confirmed cases of BSE in domestic cattle was injected into C57B1-J6 mice of the same source as used in the current study (G.A.H. Wells and M. Dawson, unpub, data). These results contrast with those from a previous study (13) in which 20 of 21 C57B1 mice were positive for spongiform encephalopathy after injection of formalin-fixed brain from the index case of TSE in greater kudu (kudu A664), with a mean incubation period of 465 [+ or -] 14 days (M. Bruce, pers. comm.). We conclude that the low incidence of positive mice in certain tissue groups is due to a lower titer of infectious agent within these tissues when compared with the CNS or ileum.

The distribution of BSE infectivity in tissues of greater kudu contrasts with that in tissues of BSE-infected cattle (24,25) but is more like the distribution found in genetically susceptible sheep infected with scrapie or experimental BSE (26-28). In field cases of cattle with BSE, infectivity has been found only in the CNS (25), but in cattle experimentally challenged orally with the agent of BSE, ileum and bone marrow have also been shown to contain infectivity (21,24,29). In classical studies of scrapie in sheep and goats, infectivity was detected in the nervous and lymphoreticular systems, placenta, adrenal gland, nasal mucosa, lung, pancreas, liver, bone marrow, thymus, and alimentary tract, although most of the non-neural, non lymphoreticular peripheral tissues contained only low titers of agent (30,31).

The finding of infectivity in kudu skin, conjunctiva, and submandibular salivary gland was unexpected as these tissues have not been previously shown to be infective in scrapie, BSE, or any naturally occurring TSE. Nonetheless, infectivity has been found previously in salivary glands of mice after injection of infected tissues with a high titer of scrapie agent (32) and of mink injected with the transmissible mink encephalopathy agent (33). In experimentally-induced transmissible mink encephalopathy, low concentrations of agent occurred in liver, kidney, intestine, and salivary gland only after replication in the CNS and in some lymphoreticular tissues (33). The inconsistent observation of low levels or traces of infection in certain non-neural and non-lymphoreticular tissues is in general a feature of both natural and experimental TSE. Given the relative paucity of data on the tissue distribution of infectivity in TSEs, the finding of infection in any given tissue should probably not be regarded as surprising. The infectivity of a certain tissues subsequent to CNS involvement may be a rare event incidental to the pathogenesis of the disease.

We have previously indicated that the epidemiology of BSE in the small kudu herd at London Zoo was consistent with either a particularly high susceptibility to infection, the occurrence of direct animal-to-animal transmission of the disease, or with a combination of these factors (2,14,15). The presence of infectivity in tissues, such as the skin and salivary gland, suggests possible routes by which direct transmission could occur. Eklund et al. (32), for example, suggested infection of the salivary gland as an explanation for contact infection of scrapie between mice.

Given the extended survival period range with BSE in the C57B1-J6 mice used in the current study compared to the incubation periods in C57B1 mice used previously (13) and the relative insensitivity of the mouse model (24), these results may be an underestimate of the extent of infectivity in the kudu tissues assayed. A recently reported rapid immunoassay shown to be capable of detecting Pr[P.sub.BSE] in the brainstems of cattle with a sensitivity similar to that of the infectivity levels determined by end-point titration in Tg(BoPrP) mice (34) possibly offers prospects for more sensitive detection of disease-related PrP as a proxy for infectivity bioassay. An important area for further research, therefore, is to investigate whether our results represent true qualitative differences in the biology of BSE in the greater kudu and the domestic cow or possibly indicate similarities, unapparent only because of the variables inherent in the sensitivities of current bioassay methods.
Table 1. Species of zoo animal with confirmed novel spongiform
encephalopathy acquired contemporaneously with epidemic of
bovine spongiform encephalopathy in domestic cattle (a)

Species No. of cases Reference

Bovidae
 Nyala, Tragelaphus angasi 1 1
 Greater kudu, Tragelaphus 6 2
 strepsiceros
 Gemsbok, Oryx gazella 1 1
 Arabian oryx, Oryx leucoryx 1 3
 Scimitar-horned oryx, Oryx 1 2
 dammah
 Eland, Taurotragus oryx 6 2,4
 American bison, Bison bison 1 5
Felidae
 Cheetah, Acinonyx jubatus 10 (b) 2,5-8
 Puma, Felis concolor 3 2,9
 Ocelot, Felis pardalis 3 4,5
 Tiger, Panthera tigris 3 5
 Lion, Panthera leo 4 4,5
 Asian golden cat, Catopuma 1 (c) 10
 temminckii

(a) Animals were born and cases occurred in Great Britain unless stated
otherwise.

(b) The initial case of transmissible spongiform encephalopathy in a
cheetah occurred in Australia, one case in the Republic of Ireland, and
three cases in France; all animals were born in Britain except the most
recently reported case in France.

(c) Reported from Australia, born in Germany, and kept for a period in
the Netherlands (10)

Table 2. Bioassay results for greater kudu tissues injected into
C57BI-J6 mice

Kudu Positive
identification no. Tissue (a) injected mice/total (b)

A1212 Rostral cerebrum 13/20
 Cranial thoracic spinal cord 19/20 (d)
 Lumbar spinal cord 15/19
 Spleen 3/11 (d)
 Retropharyngeal lymph node 6/11 (d)
 Popliteal lymph node 0/20 (d)
 Visceral lymph nodes (pool) 14/18
 Submandibular lymph node 0/20 (d)
 Distal ileum 11/20
 Lung 1/14 (d)
 Kidney 0/18
 Caruncular endometrium 0/20 (d)
 Ovary 0/20
 Mammary gland 0/20 (d)
 Submandibular salivary gland 1/17 (d)
 Conjunctiva 1/16 (d)
 Nasal mucosa 0/20
 Skeletal muscle 0/19 (d)
 (biceps brachii + vastus
 lateralis)
 Skin (flank) 2/18 (d)
 Feces 0/11
 Serum 0/19
A664 Spleen (P) 1/8 (d)
 Visceral lymph nodes (pool) 6/15 (d)
 (P)
 Lung (P) 0/20
 Kidney (P) 0/20
 Skeletal muscle (P) 0/19
A1221 Brainstem 10/18
 Kidney 0/20
 Skeletal muscle (vastus 0/19
 lateralis) (F)
A1221 +A666 (pool) Spleen (pool) 0/20
 Visceral lymph nodes 10/18
 (pool)
 Lung (pool) (F) 0/19

 Mean survival
 period post
Kudu injection (days)
identification no. Tissue (a) injected [+ or -] SD (c)

A1212 Rostral cerebrum 595 [+ or -] 84
 Cranial thoracic spinal cord 557 [+ or -] 121
 Lumbar spinal cord 521 [+ or -] 69
 Spleen 819 [+ or -] 41
 Retropharyngeal lymph node 784 [+ or -] 77
 Popliteal lymph node N/A (e)
 Visceral lymph nodes (pool) 622 [+ or -] 114
 Submandibular lymph node N/A
 Distal ileum 547 [+ or -] 98
 Lung N/A
 Kidney N/A
 Caruncular endometrium N/A
 Ovary N/A
 Mammary gland N/A
 Submandibular salivary gland N/A
 Conjunctiva N/A
 Nasal mucosa N/A
 Skeletal muscle N/A
 (biceps brachii + vastus
 lateralis)
 Skin (flank) 713 [+ or -] 22
 Feces N/A
 Serum N/A
A664 Spleen (P) N/A
 Visceral lymph nodes (pool) 843 [+ or -] 113
 (P)
 Lung (P) N/A
 Kidney (P) N/A
 Skeletal muscle (P) N/A
A1221 Brainstem 634 [+ or -] 62
 Kidney N/A
 Skeletal muscle (vastus N/A
 lateralis) (F)
A1221 +A666 (pool) Spleen (pool) N/A
 Visceral lymph nodes 700 [+ or -] 108
 (pool)
 Lung (pool) (F) N/A

Kudu Survival period
identification no. Tissue (a) injected range (d) (c)

A1212 Rostral cerebrum 428-745
 Cranial thoracic spinal cord 413-821
 Lumbar spinal cord 432-634
 Spleen 773-851
 Retropharyngeal lymph node 691-921
 Popliteal lymph node N/A
 Visceral lymph nodes (pool) 448-860
 Submandibular lymph node N/A
 Distal ileum 426-718
 Lung 746
 Kidney N/A
 Caruncular endometrium N/A
 Ovary N/A
 Mammary gland N/A
 Submandibular salivary gland 599
 Conjunctiva 659
 Nasal mucosa N/A
 Skeletal muscle N/A
 (biceps brachii + vastus
 lateralis)
 Skin (flank) 697-728
 Feces N/A
 Serum N/A
A664 Spleen (P) 929
 Visceral lymph nodes (pool) 649-952
 (P)
 Lung (P) N/A
 Kidney (P) N/A
 Skeletal muscle (P) N/A
A1221 Brainstem 541-762
 Kidney N/A
 Skeletal muscle (vastus N/A
 lateralis) (F)
A1221 +A666 (pool) Spleen (pool) N/A
 Visceral lymph nodes 455-851
 (pool)
 Lung (pool) (F) N/A

(a) Tissues not prepared fresh are suffixed: (F), fixed, (P), paraffin
wat embedded.

(b) Number of mice positive/number of mice surviving when the first
mouse was confirmed positive by histopathologic or immunochemical
examination. The denominator for negative groups is the number of mice
examined.

(c) Survival periods of positive mice determined positive either by
histopathologic or immunohistochemical examination results.

(d) Mice examined by Pr[P.sup.Sc] immunohistochemical examinations.

(e) N/A, not applicable.

Table 3 Details of spongiform encephalopathy-positive greater kudu used
for mouse inoculation studies

 Age at
Kudu ref no. death (mo) Sex

A664 30 F
A666 37 M
A1221 18 M
A1212 39 F

Kudu ref no. Brief history

A664 Born at London Zoo. Died after progressive
 neurologic disease of approximately 72 hours.
 Examined postmortem on the same day.
A666 Born at London Zoo. Killed after progressive
 neurologic disease of approximately 24 hours.
 Examined postmortem on the same day.
A1221 Born at London Zoo. Killed for management
 reasons as a clinically healthy animal and
 immediately examined postmortem.
A1212 Born in Britain, moved to London Zoo at 12 months
 of age. Killed following progressive neurologic
 disease lasting approximately 1 month and
 immediately examined postmortem.

Kudu ref no. Basis of diagnosis

A664 Histopathologic examination of brain and
 experimental transmission to mice
A666 Histopathologic, SAF, and Pr[P.sup.Sc]
 immunocytochemical examinations of the
 brain and spinal cord (a)
A1221 Histopathologic, SAF, and Pr[P.sup.Sc]
 immunocytochemical examinations of the
 brain and spinal cord
A1212 Histopathologic and SAF examinations of
 the brain

(a) SAF, scrapie-associated fibrils; Pr[P.sup.Sc], transmissible
spongiform encephalopathy disease-specific form of the PrP protein.


Acknowledgments

We thank the staff of the Veterinary Laboratories Agency-Weybridge for technical support.

The study was funded by the former Ministry of Agriculture, Fisheries and Food.

References

(1.) Jeffery M, Wells GAH. Spongiform enccphalopathy in a nyala (Tragelaphus angasi). Vet Pathol. 1988;25:398-9.

(2.) Kirkwood JK, Cunningham AA. Epidemiological observations on spongiform encephalopathies in captive wild animals in the British Isles. Vet Rec. 1994;135:296-303.

(3.) Kirkwood JK, Wells GAH, Wilesmith JW, Cunningham AA, Jackson SI. Spongiform encephalopathy in an Arabian oryx (Oryx leucoryr) and a greater kudu (Tragelaphus strepsiceros). Vet Rcc. 1990;127:418-20.

(4.) Department for Environment, Food and Rural Affairs. BSE information. 2002; Available from: http://www.defra.gov.uk/animalh/bse/ bse-statistics/level-3-tsestat.html

(5.) Kirkwood JK, Cunningham AA. Spongiform encephalopathies in captive wild animals in Europe, 1986-99. In: Proceedings of the 26th World Veterinary Congress, Lyon; 1999 Sept 23-26. World Veterinary Association; 1999.

(6.) Baron T, Belli P, Madec JY, Moutou F, Vitaud C, Savey M. Spongiform encephalopathy in an imported cheetah in France. Vet Rec. 1997;141:270-1.

(7.) Vitaud C, Flach E J, Thornton SM, Capello R. Clinical observations in four cases of feline spongiform encephalopathy in cheetahs (Acionyx jubatus). European Association of Zoo and Wildlife Veterinarians (EAZWV) Second scientific meeting May 21-24, 1998. Chester, UK. p. 133-8.

(8.) Lezmi S, Bencsik A, Monks E, Petit T, Baron T. First case of feline spongiform encephalopathy in a captive cheetah born in France: PrPsc analysis in various tissues revealed unexpected targeting of kidney and adrenal gland. Histochem Cell Biol. 2003;119:415-22.

(9.) Willoughby K, Kelly DF, Lyon DG, Wells GAH. Spongiform encephalopathy in a captive puma (Felis concolor). Vet Rec. 1992;131:431-4.

(10.) Young S, Slocombe RE Priori-associated spongiform encephalopathy in an imported Asiatic golden cat (Catopuma temmincki). Aust Vet J. 2003;81:295-6.

(11.) Buns N, Mestre-Frances N, Belli E Cathala F, Gajdusek DC, Brown P. Natural and experimental oral infection of nonhuman primates by bovine spongiform encepbalopathy agents. Proc Natl Acad Sci U S A. 1999;96:4046-51.

(12.) Baker HF, Ridley RM, Wells GAH, Ironside JW. Spontaneous spongiform encephalopathy in a monkey. Lancet. 1996;348:955-6.

(13.) Brace M, Chree A, McConnell I, Foster J, Pearson G, Fraser, H. Transmission of bovine spongiform encephalopathy and scrapie to mice: strain variation and the species barrier. Philos Trans R Soc Lurid B Biol Sci. 1994;343:405-11.

(14.) Kirkwood JK, Cunningham AA, Wells GAH, Wilesmith JW, Barnett JEF. Spongiform encephalopathy in a herd of greater kudu Tragelaphus strepsiceros: epidemiological observations. Vet Rec. 1993;133:360-4.

(15.) Cunningham AA, Wells GAH, Scott AC, Kirkwood JK, Barnett JEF. Transmissible spongiform encephalopathy in greater kudu (Tragelaphus strepsiceros). Vet Rec. 1993;132:68.

(16.) Kirkwood JK, Cunningham AA, Austin AR, Wells GAH, Sainsbury AW. Spongiform encephalopathy in a greater kudu (Tragelaphus strepsiceros) introduced into an affected group. Vet Rec. 1994;134:167-8.

(17.) Brown P, Rohwer RG, Green EM, Gajdusek DC. Effect of chemicals, heat and histopathological processing on high-infectivity hamster-adapted scrapie virus. J Infect Dis 1982;145:683-7.

(18.) Fraser H, Bruce ME, Chree A, McConnell 1, Wells, GAH. Transmission of bovine spongiform encephalopathy and scrapie to mice. J Gen Virol. 1992;73:1891-7.

(19.) Wells GAll, Dawson M, Hawkins SAC, Austin AR, Green RB, Dexter 1, et al. Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy. In: Gibbs CJ, editor. Bovine spongiform encephalopathy: the BSE dilemma. New York: Springer-Verlag; 1996. p. 28-44.

(20.) Dickinson AG, Meikle VMH, Fraser H. Identification of a gone which controls the incubation period of some strains of scrapie agent in mice. J Comp Pathol 1968;78:293-9

(21.) Wells GAH, Hawkins SAC, Green R B, Spencer YI, Dexter I, Dawson M. Limited detection of sternal bone marrow infectivity in the clinical phase of experimental bovine spongiform encephalopathy (BSE). Vet Rec. 1999;144:292-4.

(22.) Wells GAH, Hawkins SAC, Austin AR, Ryder SJ, Done Ski, Green RB, et al. Studies of the transmissibility of the agent of bovine spongiform encephalopathy to pigs. J Gen Virol. 2003;84:1021-31.

(23.) Fraser H, McBride PA. Parallels and contrasts between scrapie and dementia of the Alzheimer type and ageing: strategies and problems for experiments involving lifespan studies. In: Traber J, Gispen WH, editors. Senile dementia of the Alzheimer type. Berlin: Springer-Verlag; 1985. p. 250-68.

(24.) Wells GAH, Hawkins SAC, Green RB, Austin AR, Dexter I, Spencer YI, et al. Preliminary observations on the pathogenesis of experimental bovine spongiform encephalopathy (BSE): an update. Vet Rec. 1998;142:103-6.

(25.) Fraser H, Foster J. Transmission to mice, sheep and goats and bioassay of bovine tissues. In: Transmissible spongiform encephalopathies. A consultation on BSE with the Scientific Veterinary Committee of the Commission of the European Communities held in Brussels, September 14-15, 1993. Bradley R, Marchant B, editors. Document VI/4131/94-EN. Brussels, European Commission Agriculture. 1994. p. 145-159.

(26.) European Commission. Update of the opinion on TSE infectivity distribution in ruminant tissues (Initially adopted by the Scientific Steering Committee at its meeting of January 10-11, 2002 and amended at its meeting of November 7-8, 2002) following the submission of (1) a risk assessment by the German Federal Ministry of Consumer Protection, food and Agriculture and (2) new scientific evidence regarding BSE infectivity distribution in tonsils; 2002. Available from: http://europa.eu.int./comm/food/fs/sc/ssc/outcome_en.html

(27.) Foster JD, Parnham DW, Hunter N, Brace M. Distribution of the prion protein in sheep terminally affected with BSE following experimental oral transmission. J Gen Virol. 2001;82:231-26.

(28.) Jeffrey M, Ryder S, Marlin S, Hawkins SAC, Terry L, BerthelinBaker C, el al. Oral inoculation of sheep with the agent of bovine spongiform encephalopathy (BSE). 1. Onset and distribution of disease-specific PrP accumulation in brain and viscera. J Comp Pathol. 2001;124:280-9.

(29.) Wells GAH, Dawson M, Hawkins SAC, Green RB, Dexter 1, Francis ME, et al. Infectivity in the ileum of cattle challenged orally with bovine spongiform enccphalopatby. Vet Rec. 1994;135:40-1.

(30.) Hadlow WJ, Kennedy RC, Race RE. Natural infection of Suffolk sheep with scrapie virus. J Infect Dis. 1982;146:657-64.

(31.) Hadlow W J, Kennedy RC, Race RE, Eklund CM. Virologic and neurohistologic findings in dairy" goats affected with natural scrapie. Vet Pathol. 1980;17:187-99.

(32.) Eklund CM, Kennedy RC, Hadlow WJ. Pathogenesis of scrapie virus infection in the mouse. J Infect Dis. 1967;117:15-22.

(33.) Hadlow WJ, Race RE, Kennedy RC. Temporal distribution of transmissible mink encephalopathy virus in mink inoculated subcutaneously. J Virol. 1987;61:3235-40.

(34.) Safar JG, Scott M, Monaghan J, Deering C, Didorenko S, Vergara J, et al. Measuring prions causing bovine spongiform encephalopathy or chronic wasting disease by immunoassays and transgenic mice. Nat Biotechnol. 2002;20:1147-50.

Andrew A. Cunningham, * James K. Kirkwood, * (1) Michael Dawson, ([dagger]) 2 Yvonne I. Spencer, ([dagger]) Robert B. Green, ([dagger]) and Gerald A.H. Wells ([dagger])

* Institute of Zoology, Regent's Park, London, United Kingdom; and

([dagger]) Veterinary Laboratories Agency, Addlestone, Surrey, United Kingdom

(1) Present affiliation is Universities Federation for Animal Welfare, Wheathampstead, Hertfordshire, UK.

(2) Present affiliation is National Scrapie Plan Administration Centre, Worcester, UK.

Dr. Cunningham, a veterinary pathologist, is a senior research fellow and head of Wildlife Epidemiology at the Institute of Zoology, Zoological Society of London. His research interests include emerging infectious diseases of wildlife and disease threats to biodiversity conservation.

Address for correspondence: Andrew Cunningham, Institute of Zoology, Regent's Park, London NWI 4RY, UK; fax: +44-0-20-7586-1457; email: A.Cunningham@ioz.ac.uk
COPYRIGHT 2004 U.S. National Center for Infectious Diseases
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2004, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:Research
Author:Wells, Gerald A.H.
Publication:Emerging Infectious Diseases
Date:Jun 1, 2004
Words:4422
Previous Article:Mycobacterium ulcerans treatment costs, Australia.
Next Article:Nursing home residents and enterobacteriaceae resistant to third-generation cephalosporins.
Topics:


Related Articles
Brain killer stable in soil.
Mad cow disease diagnosed in humans.
Mad cow disease, human illness tied.
Bovine Spongiform Encephalopathy and Variant Creutzfeldt-Jakob Disease: Background, Evolution, and Current Concerns.
Nutrition hotline: this month's nutrition hotline concerns the transmission of mad cow disease through dairy products.
Tests explore next generation of defenses. (Mad Cow Future).
Mad cow testing.
After two years, beef moo-ving across the border.
Hunter beware: infectious proteins found in deer muscle.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters